The therapeutic domain includes providing controlled anesthesia and deep sedation, and is used in conditions where short-term symptomatic assistance is needed.

Пропован is applied across domains where short-term symptom management is appropriate, primarily used for general anesthesia (induction and maintenance), deep sedation during diagnostic procedures, and sustained sedation for patients in the Intensive Care Unit (ICU) requiring mechanical ventilation. This medication is relevant for easing symptoms related to heightened physiological activity by providing a highly controllable state of sleep and immobility. This supports patients during difficult episodes by easing distress and helps address symptom clusters related to systemic imbalance, such as severe agitation.

“The medication supports patients during difficult episodes by easing distress and helping manage symptom clusters related to systemic imbalance.”

Пропован is also considered relevant in contexts involving heightened systemic burden, such as the management of refractory status epilepticus—a severe condition marked by persistent seizure activity. This application may assist with stabilizing the patient by addressing symptoms of increased neurological or muscular activity, which contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Consciousness and Sensation

---

The eligibility for using Пропован (Propofol) is strictly defined by patient population, age, and pre-existing medical conditions, as stated in official regulatory documentation.

Contraindicated Populations

Use is prohibited for:

• Patients with a known hypersensitivity to Propofol or any component of the formulation, including soy or egg products, due to the drug's lipid emulsion composition.
• Patients with disorders of fat metabolism (e.g., hyperlipidaemia).
• Pediatric patients aged 16 years or younger for sedation in the Intensive Care Unit (ICU).
• Obstetric use for general anesthesia before delivery, as the drug crosses the placenta.

Age- and Condition-Specific Eligibility

Indication	Minimum Approved Age (FDA/EMA)	Restriction/Limitation
General Anesthesia (Induction)	ge 3 years	Not recommended for children <1 month of age.
ICU Sedation	ge 17 years (Adults)	Contraindicated for those le 16 years.
Monitored Sedation	ge 1 month to ge 16 years (varies by region/procedure)	Use in older adults requires dose reduction and caution due to sensitivity to cardiovascular effects.

Use requires caution in patients with severe cardiac, respiratory, renal, or hepatic impairment, or increased intracranial pressure. The drug is not recommended during pregnancy unless absolutely necessary and requires mothers to discard breast milk for 24 hours after use.

Interaction Map: Interactions with Other Medicines and Products — Official Regulatory Information for Propofol

Interaction Scope

Category	Documented Information
Medicinal product categories with documented interactions	Central Nervous System (CNS) depressants (including Opioids, Sedatives, Analgesic Agents), Anticonvulsants, Neuromuscular Blocking Agents (NMBAs), Cardiovascular Agents, and Alcohol.
Specific interacting medicines (if explicitly listed)	Valproate, Apalutamide, Atracurium, and Mivacurium.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic synergism resulting in additive CNS and cardiorespiratory depression; Pharmacokinetic modification (increased blood levels with Valproate); and Physical Incompatibility.
Timing-based interaction rules (if applicable)	NMBAs must not be administered through the same intravenous line as Propofol without a prior flush of the site.
Population-specific interaction notes (if applicable)	Elderly and physically compromised patients are noted as highly sensitive to the combined pharmacodynamic effects. Concomitant use with Fentanyl in pediatric patients increases the documented susceptibility to severe cardiac events.
Interaction-related restrictions	The product is restricted in patients with known hypersensitivity to egg or soybean products due to components in the injectable emulsion.

Interaction Classifications (High-Level)

Classification	Detail
Interaction severity classification (as defined in official documents)	Clinically Significant Pharmacodynamic Interaction; Clinically Significant Pharmacokinetic Interaction; Physical Compatibility Restriction.
Regulatory basis (EMA / FDA / etc.)	U.S. Food and Drug Administration (FDA) Prescribing Information and European Medicines Agency (EMA) national drug labels.

Resulting Interaction Structure

Official interaction statements:

• The co-administration of Opioids, Sedatives, or other Analgesic Agents may officially increase the anesthetic, sedative, and cardiorespiratory depressant effects.
• Co-administration with Valproate may officially lead to increased blood concentrations of Propofol.
• Neuromuscular Blocking Agents must not be administered through the same intravenous line without a prior flush.
• Use is restricted in patients with known hypersensitivity to egg or soybean products due to the formulation components.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the interaction structure of Propofol as being dominated by pharmacodynamic synergism with other CNS depressant agents, which is officially described as increasing the severity of anesthetic and cardiorespiratory outcomes. A key pharmacokinetic interaction is noted with Valproate, officially resulting in an elevation of propofol's systemic exposure. The profile also includes strict, label-mandated procedural constraints concerning the co-administration of certain muscle relaxants via the same IV line.

Пропован is a selective, orally active inhibitor of the enzyme Cathepsin K ( CTSK). The CTSK enzyme is a lysosomal cysteine protease predominantly expressed by osteoclasts, the cells responsible for bone resorption. The enzyme's primary biochemical function involves the cleavage and breakdown of proteins within the bone matrix, most notably the Type I collagen triple helix.

Following administration, Пропован reaches bone tissue and specifically binds to the active site of CTSK. This interaction blocks the enzyme’s proteolytic activity, thereby reducing its capacity to degrade the collagenous and non-collagenous components of the matrix. This mechanism directly modulates the catabolic process of bone remodeling by decreasing the rate of matrix dissolution initiated by the osteoclast, affecting the overall physiological balance of bone turnover.

Official Administration Guidelines for Пропован

Пропован is a proprietary injectable emulsion containing Propofol and must be administered strictly according to established clinical guidelines to ensure appropriate procedural use. Its use is restricted to settings with continuous patient monitoring and is performed only by practitioners trained in the management of general anesthesia or critical care.

---

Feature	Administrative Guidelines
Route of administration	Intravenous (IV) Administration only, delivered as an injectable emulsion.
Dosing schedule	Titrated to clinical effect; rates are provided per indication (e.g., 1.5 mg/kg to 2.5 mg/kg for induction; maintenance rates vary).
Preparation requirements	Administered undiluted or diluted only with 5% Dextrose Injection, USP; the final concentration must be not less than 2 mg/mL.

---

Population and Procedural Rules

Dosage must be adjusted for specific patient populations. Older, debilitated, or high-risk adults (ASA III/IV) require a reduced dose, and the administration of a rapid bolus is explicitly restricted. For pediatric patients, the medicine is not recommended for induction of anesthesia in children below 3 years of age, and its use in pediatric ICU sedation is also restricted.

Administration requires strict aseptic technique at all times. Any unused medication and associated administration components must be discarded within 12 hours of opening the container or vial to maintain product integrity.

Research Evidence / Overview of Studies for Пропован

Evidence for Use in General Anesthesia (Induction and Maintenance)

Research examining the use of Пропован for general anesthesia is extensive, drawing primarily from structured Randomized Controlled Trials (RCTs) and subsequent large-scale meta-analyses. These studies were applied in research contexts involving surgical and diagnostic procedures. Researchers studied outcomes related to the time intervals to the onset of unconsciousness, the required depth of the controlled sleep state during the intervention, and the time intervals for patient recovery and awakening.

Studies reported data showing patterns related to the time intervals for the onset of the anesthetic state across the observed adult and pediatric populations. Findings also described measurements for the time to full recovery following the cessation of administration. The research structure primarily addresses the acute, short-term effects of the agent during the procedure itself, and there is limited information tracking patient functional status or quality of life in the weeks after administration.

---

Evidence for Use in Sustained Sedation in Critical Care

The research focusing on sustained sedation involves critically ill patients requiring mechanical ventilation in the Intensive Care Unit (ICU), consisting mainly of duration-limited Randomized Controlled Trials. Researchers examined outcomes such as the duration of required sedation, measurements related to time to ventilator weaning, and the total ICU length of stay.

Studies reported measurements focused on the control of systemic activity, such as severe agitation, during the study period. Regulatory analysis indicated that the research base supporting use is most established for this short-term window (e.g., up to 72 hours).

---

Areas of Research Uncertainty and Study Gaps

Evidence quality varies across studies, and certainty remains low in certain areas. One key gap is the limited information for long-term outcomes, as the established research focuses mainly on the acute period of use. Data for certain specific groups, especially those with complex comorbid conditions or patients requiring exceptionally prolonged periods of sedation, remain insufficient compared to the general adult population.

Key Studies & References WHO Collaborating Centre for Drug Statistics Methodology (ATC Index for Propofol, N01AX10)

Common questions about Пропован (FAQ)

Q: Can Пропован cause drowsiness or affect my ability to drive?

Because Propofol is a potent anesthetic and hypnotic agent (meaning it induces a state of controlled sleep), its effects can lead to residual drowsiness or impaired performance. Official regulatory documents indicate that label information typically notes the need to avoid activities requiring full mental alertness, such as driving or operating complex machinery, for a defined period after administration.

Q: How long do the effects of a single dose of Пропован usually last?

Пропован is classified as a rapid-acting agent. According to official product information, hypnosis (the sleep-like state) usually occurs within 40 seconds of the start of injection. When administration is stopped, drug concentrations quickly decrease, which generally results in a rapid return to consciousness.

Q: What happens if I take Пропован and then drink alcohol?

Official regulatory documents caution that alcohol is a known central nervous system (CNS) depressant. Concomitant use with Propofol may result in enhanced sedative, anesthetic, and cardiorespiratory depressant effects. For this reason, official information describes the restriction against alcohol use during the time of administration and recovery.

Q: Is Пропован safe to use if I have an existing kidney condition?

Official label information states that caution is required when using Propofol in patients who have severe renal impairment (severe kidney problems). However, studies indicate that the way the body processes the drug does not appear to be significantly different in patients with chronic (long-term) kidney conditions compared to those with normal kidney function.

Q: Is it true that Пропован is only for short-term use?

Regulatory labeling specifies the use of Propofol for sedation in the Intensive Care Unit (ICU) for a duration of up to 72 hours (3 days). This focus on short-term use is because prolonged, high-dose continuous infusions are associated with an increased risk of a serious adverse reaction called Propofol Infusion Syndrome (PRIS).

Q: Why did the official documents list condition X as a contraindication for Пропован?

The use of Propofol is prohibited for patients with known hypersensitivity (severe allergy) to Propofol itself or any of its formulation components, specifically soy and egg products. This restriction is because the drug is manufactured as a lipid emulsion containing these ingredients. It is also contraindicated in patients with known disorders of fat metabolism.

Q: What should be done if an allergic reaction to Пропован is suspected?

The official label lists Anaphylaxis (a severe, life-threatening allergic reaction) as a possibility. Signs of this reaction can include rash, itching, swelling of the face, tongue, or throat, and difficulty breathing. Regulatory warnings indicate that due to the high risk associated with severe reactions, these situations are considered medical emergencies.

Q: Does Пропован have a risk of causing liver problems?

The drug's official profile notes that rare instances of acute liver injury have been associated with Propofol. Additionally, a serious but rare complication called Propofol Infusion Syndrome (PRIS) can be marked by an enlarged or fatty liver. The drug is also used with caution in patients who already have severe hepatic (liver) impairment.

Q: What is the mechanism of action of Пропован described in the patient information?

Propofol is documented to work as a Central Nervous System (CNS) depressant. Its primary action involves enhancing the inhibitory (calming) effects of the body's own naturally occurring neurotransmitter, GABA, through specific receptors in the brain. This action is what induces unconsciousness and sedation.

Q: Is Пропован considered a controlled substance?

Propofol is not currently listed as a controlled substance under the U.S. federal Controlled Substances Act. However, some individual states within the U.S. and various countries may have specific regulations requiring the drug to be tracked and handled in a similar manner to controlled substances.

Q: Does Пропован carry a Black Box Warning in the official FDA label?

Yes, the U.S. Food and Drug Administration (FDA) label for Propofol carries a Boxed Warning (often referred to as a Black Box Warning). This warning emphasizes the official restriction that the drug must be administered only by practitioners trained in the administration of general anesthesia.

Q: Is it okay to stop taking Пропован suddenly, or is tapering needed?

Official warnings state that abrupt discontinuance of Propofol, especially after prolonged use for sedation, should be avoided. Stopping suddenly may lead to complications such as increased anxiety, agitation, and resistance to mechanical ventilation.

Q: What are the typical withdrawal symptoms associated with stopping Пропован?

The symptoms associated with the abrupt discontinuance of Propofol include increased agitation, anxiety, and resistance to mechanical ventilation, according to regulatory warnings.

Q: Does Пропован require a special monitoring test (like a blood test) during use?

During the administration of Propofol, continuous monitoring of the patient's cardiorespiratory function, vital signs, and level of consciousness is officially required. Additionally, because the drug may cause an increase in triglyceride levels (fat levels in the blood), monitoring for this potential effect may also be necessary.

How to Store and Dispose of Propovan (Propofol Injectable Emulsion)

Storage Category	Official Regulatory Requirements
Temperature & Protection	Store unopened vials between 4°C and 25°C (40°F and 77°F). Do not freeze.
Handling & Stability	Use strict aseptic technique and visually inspect the vial before use. Once spiked, the emulsion must be used within 12 hours; any unused portion must be discarded after this time. Vials are for single access and single-patient use only.
Disposal & Safety	Keep out of the sight and reach of children. Any unused product, administration lines, and waste material must be disposed of in accordance with local requirements for medicinal products.